source
- #ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T updateCHICAGO — Eli Lilly in April signed an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy ...Endpoints · 1mo ago↗ source
- After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listingAvenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. The Monday morning deal comes ...Endpoints · 1mo ago↗ source
- STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and moreDetailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months